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TDP-43p97/VCP/Cdc48 is one of the best-characterized type II AAA (ATPases associated with diverse cellular
activities) ATPases. p97 is suggested to be a ubiquitin-selective chaperone and its key function is to
disassemble protein complexes. p97 is involved in a wide variety of cellular activities. Recently, novel
functions, namely autophagy and mitochondrial quality control, for p97 have been uncovered. p97 was
identiﬁed as a causative factor for inclusion body myopathy associated with Paget disease of bone and
frontotemporal dementia (IBMPFD) and more recently as a causative factor for amyotrophic lateral sclerosis
(ALS). In this review, we will summarize and discuss recent progress and topics in p97 functions and the
relationship to its associated diseases. This article is part of a Special Issue entitled: AAA ATPases: structure
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p97—also called valosin-containing protein (VCP) in mammals,
Cdc48p in yeast, or CDC-48 in Caenorhabditis elegans—is well conserved
among all eukaryotes and is essential for growth in Saccharomyces
cerevisiae[1], Drosophila melanogaster[2], C. elegans[3] and mice [4]. p97
is highly abundant, accounting for about 1% of the total cellular protein.
p97 belongs to the type II AAA (ATPases associatedwith diverse cellular
activities) family [5–7]. p97 is composed of a substrate and cofactor
bindingNdomain followed by twoAAAATPase domains termedD1 and
D2, and forms a hexameric double-ring structure [8,9]. It has been
demonstrated that the two ATPase domains are not catalytically
equivalent: D2 has the major ATPase activity at physiological temper-
atures, whereas D1 is involved in the regulation of heat-induced ATPase
activity [10]. D1 also plays a major role in hexamerization [11,12].
Recently, Nishikori et al. reported that the high D2ATPase activity is in a
coordinated fashion with positive cooperativity [13]. Given that the
growth rate of yeast cells strongly related to the positive cooperativityrather than the ATPase activity itself, it has been claimed that the
positive cooperativity is critical for p97 function [13].
It has been suggested that p97 is a ubiquitin-selective chaperone
and that its key function is to unfold proteins and disassemble
protein complexes [14]. p97 converts chemical energy generated
from ATP hydrolysis into mechanical force used for conformational
changes of target proteins as a unfoldase or a segregase [6,14–17].
p97 plays critical roles in a broad range of diverse cellular processes,
including Golgi, endoplasmic reticulum (ER), and nuclear mem-
brane reassembly [18–22], ER associated degradation (ERAD) [23–
25], the ubiquitin-proteasome system [14,26–29], cell cycle regu-
lation [22,30–33], DNA repair [34,35], preventing polyglutamine
aggregation [3,36–39], autophagosome maturation [40–43], and
mitophagy [44] (Fig. 1). Functional diversity of p97 is mainly
determinedbydifferential bindingof distinct cofactors/adaptor proteins
[45–47].
p97 has been linked to a severe degenerative disorder identiﬁed as
hereditary inclusion body myopathy associated with Paget disease of
bone and frontotemporal dementia (IBMPFD), which mostly affects
muscles and brain [48]. The pathogenesis of IBMPFD is attributed to
autosomal-dominant single-amino-acid substitutions in highly con-
served residues within the p97 N-terminal domain and D1 domain
[48,49]. Recently, p97 mutations have also been identiﬁed as a cause
of familial amyotrophic lateral sclerosis (ALS), which links p97 defects
to motor neuron degeneration [50].
p97 is a multifunctional protein and its functions are required for
cell viability. However, its precise role and mechanism for each
cellular function remain elusive. In this review, wewill focus on recent
progress in ubiquitin-mediated protein degradation, autophagy and
cell cycle, and discuss p97 functions and the relationship to p97-
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2. Protein degradation
Short-lived proteins and misfolded and damaged proteins should
be appropriately degraded by the ubiquitin-proteasome pathway.
Ubiquitin is a highly conserved protein and is involved in the post-
translational protein modiﬁcation in eukaryotes [56]. Ubiquitination
occurs on lysine residues of substrates through the cooperative
activity of ubiquitin activating (E1), ubiquitin conjugating (E2) and
ubiquitin ligase (E3) enzymes [56]. p97 is suggested to be a ubiquitin-
selective chaperone [14]. It has been demonstrated that the
interaction between p97 and E3 ubiquitin ligases, gp78 and Hrd1,
plays an important role in ERAD [57–59]. It should be mentioned that
besides ERAD substrates, degradation of soluble cytoplasmic proteins
is also mediated by the speciﬁc interaction between a p97 complex
and a distinct E3 ubiquitin ligase. Actually, it has been demonstrated
that a large number of E3 ubiquitin ligases were immunoprecipitated
with p97 cofactors UBX proteins [60]. For example, UBXD7 links p97
to CUL2/VHL ubiquitin ligase and its substrate hypoxia-inducible
factor 1α [60]. Althoughmany substrates for degradationmediated by
p97 have been identiﬁed up to date, E3 ubiquitin ligase for their
polyubiquitination remains mostly elusive. It is clear that compre-
hensive analysis of the relationship among p97 cofactors, substrates,
and E3 ubiquitin ligases is needed to globally understand p97 cellular
functions.
Genetic and biochemical analyses have revealed that the interac-
tion between p97 and E3 ubiquitin ligase plays an important role in
the C. elegans sex determination pathway [29]. C. elegans has two
sexes, self-fertilizing hermaphrodite and male. Hermaphrodites
possess ﬁve pairs of autosomes and two X chromosomes (XX),
while males possess the same ﬁve pairs of autosomes and a single X
chromosome (XO). Males begin spermatogenesis and produce sperm
continuously throughout adulthood. In contrast, hermaphrodite self-
fertility is achieved by a transient spermatogenesis during the L4 stage
followed by a switch to oogenesis to produce oocytes continuouslyFig. 1. Multiple function of p97. N-terminal cofactors involved in each function are also ind
Green, protein aggregation; Pink, cell cycle and DNA transaction.throughout adulthood. The sex determination pathway that regulates
the switching from spermatogenesis to oogenesis is composed of a
several negative regulatory factors and is in a negative regulatory
hierarchy to control TRA-1 activity [61,62]: HER-1 promotes sper-
matogenesis by binding to and inactivating the transmembrane
protein TRA-2. The cytoplasmic domain of TRA-2 binds to FEM-3,
which functions as a substrate recognition receptor for CUL-2 type E3
ubiquitin ligase in associationwith FEM-1 and FEM-2 proteins [63,64].
FEM proteins regulate the levels of TRA-1 via the ubiquitin-
proteasome degradation system [64,65]. TRA-1 is a transcription
factor that regulates fog-1 and fog-3 transcription. In hermaphrodite
germline, FOG-1 and FOG-3 would be initially ON (spermatogenesis),
but later in development, TRA-1 would be ON (oogenesis).
We found that either cdc-48.1 or cdc-48.2 deletion mutant of C.
elegansproduced less sperm, thus less progeny than thewild-type strain
[29]. It should bementioned that C. elegans uniquely possesses two p97
homologues CDC-48.1 and CDC-48.2, whose functions are redundant
but whose expression are differentially regulated [3,66,67]. The CDC-48
complex associated with UFD-1 and NPL-4 interacted with the CUL-2
complex via NPL-4 binding to Elongin C and TRA-1 accumulated in the
cdc-48.1 mutant. We proposed that C. elegans CDC-48 associated with
UFD-1 and NPL-4 plays an important role in the switching from
spermatogenesis to oogenesis by regulating CUL-2-mediated TRA-1
degradation by the proteasome [29]. Furthermore, other cofactors,
UBXN-1, UBXN-2 and UBXN-3, for CDC-48 are also involved in this
regulation [68]. Molecular mechanism of the switching seems that the
CDC-48 recognizes and binds to the ubiquitinated TRA-1 and disassem-
bles the complex containing TRA-1 as a ubiquitin-selective segregase.
How p97 acts on ubiquitinated substrates is another important
issue. The yeast transcription factors Mga2 and Spt23 are synthesized
as an ER membrane-anchored, inactive dimer for each case [26]. It has
been demonstrated that Rsp5 ubiquitin ligase, p97 associated with
Ufd1 and Npl4, and the proteasome are required for processing
precursors and mobilization of the processed, transcriptionally active
Mga2 and Spt23 molecule from their unprocessed, ER membrane-
anchored partner [14,69]. The in vitro assay system with puriﬁed
proteins has been developed and nicely demonstrated that p97icated. Yellow, function related to membrane reformation; Blue, protein degradation;
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the tetheredMga2 and Spt23 via a polyubiquitin signal present on the
membrane-anchored proteins [70]. These results clearly showed that
p97 functions as a ubiquitin-selective segregase.
It is also interesting to discuss that several deubiquitinating
enzymes that possess opposed cellular activity against ubiquitin ligase
have been shown to interact with p97, although the physiological
relevance of their interactions is yet unknown [71]. Ataxin-3 is one of
these deubiquitinating enzymes and the protein involved in
Machado-Joseph disease caused by a polyglutamine expansion
[72,73]. Ataxin-3 interacts with ubiquitinated substrates, p97,
Rad23, and the proteasome, and the expanded-polyglutamine-
containing ataxin-3 is defective in the substrate degradation [74].
Ataxin-3 and Ufd1 bind to p97 in a mutually exclusive manner and
ataxin-3, especially its deubiquitinating activity, plays an important
role in the regulation of ERAD [75,76]. Binding of ataxin-3 to p97 was
enhanced in Machado–Joseph disease and IBMPFD, whereas binding
of ubiquitin ligase was decreased [77]. Therefore, the levels of binding
to ubiquitin ligases or deubiquitinating enzymes would modify the
activity of p97 and the elucidation of these molecular mechanisms
will be a great topic in the future. Physiologically, ubiquitin chain
editing mediated by ataxin-3 is involved in the determination of
lifespan in C. elegans[78].3. Mitochondria
In themitochondrialmatrix and the innermitochondrialmembrane,
several AAAproteases, such as Lon, Yme1, Yta10 andYta12, play a role in
the degradation of misfolded or damaged proteins [79]. In contrast, the
quality control of the outer mitochondrial membrane (OMM) proteins
has not yet been elucidated. Several OMM proteins, such as anti-
apoptotic protein Mcl1 and the mitochondrial fusion protein Fzo1, are
known to beunder the control of the ubiquitin-proteasome system [80–
82]. Recently, it has been reported that a number of E3 ubiquitin ligases
including Parkin [82–84], which is mutated in an autosomal recessive
form of Parkinson's disease [85], and a deubiquitinating enzyme USP30
are associatedwithmitochondria [86]. However, in contrast to ERAD, in
which p97 associated with Ufd1–Npl4 plays a crucial role in extracting
the ER proteins into the cytosol to be degraded by the proteasome, no
such a factor has been identiﬁed.
Vms1 (VCP/Cdc48-associated mitochondrial stress-responsive
1) has been identiﬁed as a component of a Cdc48 multiprotein
complex [87] and as a mitochondrial protein [88]. Vms1 localizes
primarily to the cytoplasm, but upon the mitochondrial stress, it
translocates to the mitochondria [89]. Loss of Vms1 causes
hypersensitivity to hydrogen peroxide and rapamycin, and impairs
the OMM protein degradation [89]. Vms1 interacts with Cdc48 via
the VIM (VCP-interacting motif) domain of Vms1 and with Npl4. It is
interesting to mention that Vms1 and Ufd1 are mutually exclusive in
terms of Cdc48 binding [89]. Based on the genetic and biochemical
analyses, Heo et al. proposed that the Vms1–Npl4–Cdc48 complex
organized upon mitochondrial stress plays a role in maintaining the
mitochondrial function through protein quality control [89]. Vms1
has also been demonstrated to function in the ERAD pathway for a
subset of substrates [89,90]. Furthermore, Xu et al. reported that p97
is required for the proteasomal degradation of Mcl1 and Mfn1 (an
Fzo1 homologue) and that the ATPase activity of p97 is required for
the retrotranslocation of Mcl1 from mitochondria to the cytosol
[91]. It has also been reported that ubiquitination of Mfn1 is induced
by E3 ubiquitin ligase Parkin upon mitochondrial damage and its
degradation is mediated by p97 and proteasome [44]. Interestingly,
both p97 and proteasome activities are required for Parkin-
mediated mitophagy, an autophagic pathway speciﬁc for mitochon-
dria, of damaged mitochondria [44,92]. These results together
clearly indicate that the p97-associated ubiquitin-proteasomesystem plays an important role in the quality control of mitochon-
drial as well as ER proteins.
Vms1 is also evolutionarilywell conserved in eukaryotes. InC. elegans,
VMS-1 shows mitochondrial localization upon mitochondrial stress.
VMS-1 is dispensable for viability and growth but is required for
protection against oxidative stress and for wild-type life span [89].
4. IBMPFD pathogenesis
p97 has been linked to a severe degenerative disorder identiﬁed
as hereditary inclusion bodymyopathy associatedwith Paget disease
of bone and frontotemporal dementia (IBMPFD) [48,49,93–95]. Most
of IBMPFD mutations identiﬁed cluster at the contact sites of N and
D1 domains of p97, which are required for the transmission of
conformational changes derived from ATP hydrolysis to cofactors
and/or substrate proteins [48,49,96]. The N and D1 domains are
spatially separated and for only three direct contacts, R155-N387,
R89-E261 and E30-K217 [97] and R155 is frequently mutated in
IBMPFD [94]. Thus, some of IBMPFD mutations may alter the relative
orientation of the N and D1 domains of p97 [97]. Partial trypsin
digestion assays also revealed nucleotide-induced structural alter-
ations of the N domain in IBMPFD-associated p97 mutants [77]. The
X-ray crystallography analysis of N-D1 fragments of IBMPFD-
associated p97 mutants has revealed an atypical N domain
conformation in the presence of ATPγS and a wild-type-resembling
conformation in the presence of ADP [98]. IBMPFD-associated p97
mutants also had a reduced binding afﬁnity for ADP [98]. Tang et al.
thus proposed that IBMPFD-associated p97 mutations alter the
timing of the transition between nucleotide states by destabilizing
the ADP-bound form and consequently interfere with the interac-
tions between the N-domains and their substrates [98]. In contrast,
Manno et al. reported that IBMPFD-associated p97 mutants pos-
sessed ~1.5-fold increased ATPase activities and enhanced aggre-
gate-forming activities in cultured cells, and thus claimed that
constitutively elevated ATPase activities of p97 are primary abnor-
malities causing IBMPFD [99]. Halawani et al. also reported that
IBMPFD-associated p97 mutants exhibited an ~3-fold increase in
ATPase activity compared to wild-type and formed a normal
hexameric ring-shaped structure [100]. However, Weihl et al.
reported that IBMPFD-associated p97 mutants retained a normal
hexameric structure and ATPase activity [101]. Fernandez-Saiz and
Buchberger also reported a normal ATPase activity in IBMPFD-
associated p97 mutants [77]. Therefore, the notion that IBMPFD-
associated p97 mutants possess the elevated ATPase activity is now
controversial. However, it has been demonstrated that the elevated
binding abilities to several cofactors were observed in IBMPFD-
associated p97 mutants [77,99]. Signiﬁcantly, more p47, Npl4 and
ataxin3 bound to p97 from IBMPFD myoblasts [77]. Together with
the notion that the N domain conformation and location may be
altered in IBMPFD-associated p97 mutants [77,97,98], these results
suggest that the imbalanced cofactor association of p97may result in
IBMPFD.
At the cellular level, IBMPFD is characterized by the impaired ERAD
and the formationof ubiquitin-positive protein aggregates [97,101,102].
It is consistent with the fact that loss of p97 activity leads to the
accumulation of ubiquitinated proteins and impaired ERAD [103,104].
Janiesch et al. demonstrated that p97 is involved in myosin assembly
andmyoﬁbril organization by regulating the degradation of themyosin
assembly chaperone UNC-45 and that UNC-45 degradation was
abolished in C. elegans and the myoﬁbril formation and sarcomeric
function were impaired in IBMPFD [28]. Furthermore, recent studies
uncovered that p97 is required for autophagy [40–42]. Itwas shown that
p97 associatedwith Shp1/p47 is involved in autophagosome biogenesis
in concert with a ubiquitin like protein Atg8 in yeast [43]. Depletion of
p97 or expression of dominant-negative p97 mutant resulted in the
accumulation of p62, LC3II and immature autophagosomes, suggesting
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lysosome in human cells [40–42,105]. These results together imply that
protein quality control system and protein aggregates clearance system
are defective in IBMPFD.
Importantly, muscle tissues from IBMPFD patients and transgenic
mouse expressing IBMPFD-associated mutant p97 showed the similar
cellular pathology [106]. More recently, IBMPFD-associated mutant
p97 knock-in mouse was generated and was shown to be a useful
model since they replicated the muscle, bone and brain pathology of
IBMPFD patients [107].
In terms of protein aggregates, it is important to mention that TAR
(transactive response) DNA-binding protein 43 (TDP-43) positive
inclusionswere found in IBMPFD affected brains and co-localizedwith
ubiquitin [40,97,108–110]. TDP-43 is a highly conserved RNA-binding
protein and is involved in regulation of gene expression including
transcription, pre-mRNA splicing, RNA transport, and translation
[111–113]. TDP-43 inclusions are now considered to be a key
pathologic feature in both ALS and FTLD (frontotemporal lobar
degeneration) [114]. Many mutations in the gene encoding TDP-43
have been identiﬁed in sporadic and familial ALS [113]. TDP–43 is
predominantly localized in the nucleus but shuttles between the
nucleus and the cytoplasm to transport mRNAs to ribosomes in the
cytoplasm [115,116]. Since p97 functions as a segregase [14,70], p97
may extract TDP-43 from RNP complexes during the translation
processes to transfer it back to the nucleus. Considering that TDP-43 is
degraded by both proteasome and autophagy [117], it would
accumulate in the cytoplasm in IBMPFD cells due to the impaired
p97 activity and the impaired autophagy. By developing a Drosophila
model of IBMPFD, Ritson et al. showed the genetic interaction
between p97 and TDP-43, and cytoplasmic redistribution of TDP-43
[118]. They also demonstrated that TDP-43 redistribution from the
nucleus to the cytoplasm is sufﬁcient to induce cytotoxicity [118].
Furthermore, cytoplasmic redistribution of TDP-43 was also observed
in ALS and FTLDwith ubiquitin-positive inclusions [119]. It is plausible
that cytoplasmic redistribution of TDP-43 may mediate IBMPFD
pathogenesis. However, ubiquitin-positive and TDP-43-positive nu-
clear inclusions have also been described in IBMPFD neurons
[108,110]. Furthermore, it has been reported that both nuclear and
cytoplasmic accumulation of TDP-43 were neurotoxic in Drosophila
transgenic models and that TDP-43 toxicity may be cell type speciﬁc
[120]. How nuclear inclusions and/or cytoplasmic redistribution of
TDP-43 link to the pathological processes in IBMPFD and ALS caused
by p97 mutations remains elusive.
Recently, a new genomics technique, exome sequencing, identiﬁed
p97 mutations as a cause of familial ALS in addition of IBMPFD [50].
This fact links p97 defects to motor neuron degeneration. It was
suggested that p97 mutations may account for 1–2% of familial ALS.
Four mutations were identiﬁed: three of them are located between N
and D1 domains and are the same amino acid residues that are
mutated in IBMPFD [49,50]. The other one is novel and located in the
D2 domain of p97 [50].
By developing another Drosophila model of IBMPFD, Chang et al.
reported that while ERAD and ubiquitin-proteasome system were not
impaired, neurodegeneration was caused by the reduced cellular ATP
level [121]. Given thatATP- orADP-binding statemay changebiochemical
property of p97 and that p97 is involved in the mitochondrial quality
control as described above, it is interesting to explore the relationship
between cellular ATP level and IBMPFD pathogenesis.
5. Cell cycle and DNA transaction
p97 locates in the cytoplasm as well as the nucleus [33,122].
Although Cdc48 was originally identiﬁed as a cell division cycle factor
in yeast [30], the precise function of Cdc48 in the cell division
processes is still poorly understood. In mitosis, p97 was reported to
play roles in DNA replication, Aurora B kinase localization, chromo-some segregation, microtubule spindle disassembly, and nuclear
envelope reformation [21,22,31,33,123,124] (Fig. 1).
p97 associated with Ufd1 and Npl4 plays a role in DNA replication,
especially replication initiation [33]. Replication defects caused by the
depletion of p97, Ufd1 and/or Npl4 lead to the cell cycle progression
delay, replication stress and the DNA replication checkpoint activa-
tion. It was also claimed that the requirement of p97 for DNA
replication is independent of its roles in spindle dynamics and nuclear
assembly [33]. These results suggest that there should be at least a
couple of substrates for p97 in cell division processes. Degradation of
cyclin E and the G1-cyclin-dependent kinase inhibitor Far1, which
regulate the cell cycle G1/S transition, is mediated by p97 [27,32]. p97
is required for the metaphase-to-anaphase transition by stabilizing
separase, which cleaves cohesin components to separate sister
chromatids, in ﬁssion yeast [125]. In addition, human p97 is also
required for mitotic M-phase [104]. Another plausible substrate is
Aurora B kinase [22]. By using Xenopus egg extracts, Ramadan et al.
reported that p97 associated with Ufd1-Npl4 binds to the ubiquiti-
nated-Aurora B kinase and extracts it from chromatin, which leads to
chromatin decondensation and nuclear envelop reformation [22].
Similar defects were observed in mitosis by the depletion of p97 in C.
elegans[22,126]. Furthermore, Ufd1-Npl4 antagonized Aurora B kinase
on chromosomes during earlier mitotic stages in HeLa cells and thus
p97 associated with Ufd1-Npl4 was suggested to function as a crucial
negative regulator of Aurora B kinase early in mitosis of human
somatic cells so as to ensure faithful chromosome segregation [127].
On the other hand, Cheng and Chen reported that p97 associated with
its cofactor Shp1 promotes nuclear accumulation of PP1 phosphatase
to counteract the Aurora B kinase activity in yeast, indicating that p97
functions to balance the kinase and phosphatase activities at the
kinetochore in order to achieve stable bipolar attachment [128].
Two rounds of chromosome segregation take place duringmeiosis.
In the ﬁrst meiotic division, meiosis I, homologous chromosomes, but
not sister chromatids, are separated. Sister chromatids will be
separated in meiosis II. Therefore, the chromosome cohesion must
be selectively destroyed at the sites between homologous chromo-
somes in meiosis I, which is achieved by differential degradation of
REC-8 that is a meiotic speciﬁc subunit of meiotic cohesin in C. elegans
[129]. Degradation of cohesin is regulated via its phosphorylation. It
has been proposed that Aurora B kinase regulates the release of
chromosome cohesion via location-speciﬁc phosphorylation of the
cohesin REC-8 in C. elegansmeiosis [130]. We recently found that p97
recognizes and extracts Aurora B kinase from chromatin during
meiosis progression in C. elegans (Sasagawa et al., manuscript in
preparation). Depletion of p97 resulted in signiﬁcant expansion of
Aurora B kinase over the entire meiotic chromosomes, which leads to
the defective chromosome segregation, in meiosis I metaphase.
Although we cannot rule out the possibility that the extracted Aurora
B kinase will be degraded by the proteasome, its bulk level was not
changed by the depletion of p97. In addition, the amount and
localization of PP1 phosphatase, which opposes the Aurora B kinase
activity, were not changed by depletion of p97. These results imply
that p97 guarantees the precise localization of Aurora B kinase to the
cohesion sites of homologous chromatids at meiosis I prophase. We
have also reported that p97 plays an important role in chromosome
condensation during meiosis in C. elegans but that spindle assembly
and disassembly take place even under the p97 depletion [131]. In
terms of spindle dynamics, the role of p97 has remained controversial
[31,131,132]. It might be possible that p97 controls efﬁciency of
spindle dynamics.
It is worthmentioning that p97 interacts with three DNA helicases,
DNA unwinding factor (DUF) from Xenopus egg extracts [133], human
Werner syndrome protein (WRNp) [34,35] and HIM-6, a C. elegans
homologue of human Bloom syndrome helicase (BLM) [134]. p97
associates with WRNp in the nucleus of normal human skeletal
muscle [122]. WRNp and HIM-6 are members of a RecQ helicase
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disassembly of the complex containing DNA unwinding activity from
DNA during the processes of DNA replication, repair and/or
recombination. Alternatively, p97 may be required for chromatin
remodeling during cell division processes.
When cells are treated with UV, RNA polymerase II are stalled at
the sites of DNA lesions. To remove stalled RNA polymerase, one of its
subunits, Rpb1, is ubiquitinated by the Cul3-type E3 ubiquitin ligase
and then p97 associated with its cofactor Ubx5 and the proteasome
are recruited. Ubiquitinated Rpb1 will be extracted from RNA
polymerase II holoenzyme by p97 and degraded by the proteasome,
and other subunits will be disassembled from DNA [135].
6. Chemicals to inhibit p97 function and their application for anti-
cancer therapy
p97 is essential for growth inmost, if not all, organisms asmentioned
above [1–4]. While the temperature-sensitive mutants are available in
yeast [30], RNA interference or expression of dominant-negative
derivatives is usually applied to inhibit the p97 activity in other
organisms. If a speciﬁc p97 inhibitor is available, it will be useful as
another tool for the detailed analysis of p97 function in vitro and in vivo.
Four p97 inhibitors have been reported so far: (1) The ERAD
inhibitor Eeyarestatin I was found to directly associate with p97 and
ER [136,137]. It inhibited p97-associated deubiquitinating enzymes
as well as p97-dependent protein degradation, but not p97 ATPase
activity. It has been revealed that p97-associated deubiquitination is
involved in ERAD. (2) 2-Anilino-4-aryl-1,3-thiazole compounds
inhibited p97 ATPase activity and p97-associated protein degrada-
tion [138]. (3) The Syk inhibitor III irreversibly inhibited p97 ATPase
activity through its interaction with Cys522 within the D2 ATPase
domain of p97 and the ubiquitin-fused reporter protein [139]. (4) A
chemical agent N2,N4-dibenzylquinazoline-2,4-diamine (DBeQ) was
identiﬁed as a selective, potent, reversible, and ATP-competitive p97
inhibitor by screening a library of chemical compounds [140]. DBeQ
inhibited ERAD and autophagy, and induced apoptosis by activating
several caspases. DBeQ also showed antiproliferative activity on
human cancer cells [140,141]. It has been demonstrated that
inhibition of the ubiquitin-proteasome system and ER homeostasis
may offer attractive therapeutic possibilities for certain types of
human cancer [142]. Thus, the development of p97 inhibitors has
emerged as a therapeutic strategy for the treatment of human
cancer. It is interesting to mention that expression level of p97 is
correlated with progression, prognosis and recurrence of certain
types of cancer [143,144].Fig. 2. A general model for substrate disassembly activity of p97 in concert with ubiquitinat
chaperone machinery is then recruited and upon ATP hydrolysis, ubiquitinated substrat
Alternatively, in some cases, after extraction, ubiquitinated substrate will be deubiquitinated
ubiquitin; E1, ubiquitin activating enzyme; E2, ubiquitin conjugating enzyme; E3, ubiquitinIn summary, taken together with the facts that p97 is a ubiquitin-
selective chaperone that the interaction between p97 and E3 ubiquitin
ligase plays an important role in its function, we propose a general
model for substrate disassembly by p97 (Fig. 2). Substrate is ﬁrst
selectively ubiquitinated by the ubiquitination machinery, namely E1,
E2 and E3 enzymes. Polyubiquitination may not be always required. In
some cases, oligoubiquitination or even monoubiquitination may be
necessary for the later processes. p97 chaperone machinery associated
with Ufd1-Npl4 and some UBX cofactors is recruited after or during
ubiquitination processes. Upon ATP hydrolysis, ubiquitinated substrate
will be extracted and disassembled from the protein complex,
membrane, DNA, or RNA, and delivered to the proteasome, where it
will be ﬁnally degraded, possibly in concert with substrate shuttling
factors such as Dsk2 and Rad23. Alternatively, in some cases, after
extraction, ubiquitinated substrate will be deubiquitinated by the p97-
associated deubiquitinating enzyme and reactivated.Acknowledgement
The authors thank the grants from the Ministry of Education,
Culture, Sports, Science and Technology (MEXT) of Japan.References
[1] K.U. Frohlich, H.W. Fries, M. Rudiger, R. Erdmann, D. Botstein, D. Mecke, Yeast cell
cycle protein CDC48p shows full-length homology to the mammalian protein
VCP and is a member of a protein family involved in secretion, peroxisome
formation, and gene expression, J. Cell Biol. 114 (1991) 443–453.
[2] A. Leon, D. McKearin, Identiﬁcation of TER94, an AAA ATPase protein, as a Bam-
dependent component of the Drosophila fusome, Mol. Biol. Cell 10 (1999)
3825–3834.
[3] K. Yamanaka, Y. Okubo, T. Suzaki, T. Ogura, Analysis of the two p97/VCP/Cdc48p
proteins of Caenorhabditis elegans and their suppression of polyglutamine-
induced protein aggregation, J. Struct. Biol. 146 (2004) 242–250.
[4] J.M.M. Muller, K. Deinhardt, I. Rosewell, G. Warren, D.T. Shima, Targeted deletion
of p97 (VCP/CDC48) in mouse results in early embryonic lethality, Biochem.
Biophys. Res. Commun. 354 (2007) 459–465.
[5] F. Confalonieri, M. Duguet, A 200-amino acid ATPase module in search of a basic
function, Bioessays 17 (1995) 639–650.
[6] S. Patel, M. Latterich, The AAA team: related ATPases with diverse functions,
Trends Cell Biol. 8 (1998) 65–71.
[7] T. Ogura, A.J. Wilkinson, AAA+ superfamily ATPases: common structure-diverse
function, Genes Cells 6 (2001) 575–597.
[8] I. Rouiller, B. DeLaBarre, A.P. May, W.I. Weis, A.T. Brunger, R.A. Milligan, E.M.
Wilson-Kubalek, Conformational changes of the multifunction p97 AAA ATPase
during its ATPase cycle, Nat. Struct. Biol. 9 (2002) 950–957.
[9] B. DeLaBarre, A.T. Brunger, Complete structure of p97 valosin-containing protein
reveals communication between nucleotide domains, Nat. Struct. Biol. 10 (2003)
856–863.ion. Substrate (S) is ﬁrst selectively ubiquitinated by the ubiquitination machinery. p97
e will be disassembled from the complex and ﬁnally degraded by the proteasome.
. Substrate will be a soluble protein complex, in the membrane, or on DNA or RNA. Ub,
ligase; U, Ufd1; N, Npl4.
135K. Yamanaka et al. / Biochimica et Biophysica Acta 1823 (2012) 130–137[10] C. Song, Q. Wang, C.C. Li, ATPase activity of p97-valosin-containing protein
(VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-
induced activity, J. Biol. Chem. 278 (2003) 3648–3655.
[11] Q. Wang, C. Song, C.C. Li, Hexamerization of p97-VCP is promoted by ATP binding
to the D1 domain and required for ATPase and biological activities, Biochem.
Biophys. Res. Commun. 300 (2003) 253–260.
[12] Q. Wang, C. Song, X. Yang, C.C. Li, D1 ring is stable and nucleotide-independent,
whereas D2 ring undergoes major conformational changes during the ATPase
cycle of p97-VCP, J. Biol. Chem. 278 (2003) 32784–32793.
[13] S. Nishikori, M. Esaki, K. Yamanaka, S. Sugimoto, T. Ogura, Positive cooperativity
of the p97 AAA ATPase is critical for essential functions, J. Biol. Chem. 286 (2011)
15815–15820.
[14] M. Rape, T. Hoppe, L. Gorr, M. Kalocay, H. Richly, S. Jentsch, Mobilization
of processes, membrane-tethered SPT23 transcription factor by CDC48
(UFD1/NPL4), ubiquitin-selective chaperone, Cell 107 (2001) 667–677.
[15] S. Braun, K. Matuschewski, M. Rape, S. Thoms, S. Jentsch, Role of the ubiquitin-
selective CDC48UFD1/NPL4 chaperone (segregase) in ERAD of OLE1 and other
substrates, EMBO J. 21 (2002) 615–621.
[16] D. Halawani, M. Latterich, p97: the cell's molecular purgatory? Mol. Cell 22
(2006) 713–717.
[17] S. Jentsch, S. Rumpf, Cdc48(p97): a “molecular gearbox” in the ubiquitin
pathway? Trends Biochem. Sci. 32 (2007) 6–11.
[18] M. Latterich, K.U. Frohlich, R. Scheckman, Membrane fusion and the cell cycle:
Cdc48p participates in the fusion of ER membranes, Cell 82 (1995) 885–893.
[19] C. Rabouille, T.P. Levine, J.M. Peters, G. Warren, An NSF-like ATPase, p97, and NSF
mediate cisternal regrowth from mitotic Golgi fragments, Cell 82 (1995)
905–914.
[20] H. Kondo, C. Rabouille, R. Newman, T.P. Levine, D. Pappin, P. Freemont, G. Warren,
p47 is a cofactor for p97-mediated membrane fusion, Nature 338 (1997) 75–78.
[21] M. Hetzer, H.H. Meyer, T.C. Walther, D. Bilbao-Cortes, G. Warren, I.W. Mattaj,
Distinct AAA-ATPase p97 complexes function in discrete steps of nuclear
assembly, Nat. Cell Biol. 3 (2001) 1086–1091.
[22] K. Ramadan, R. Bruderer, F.M. Spiga, O. Popp, T. Baur, M. Gotta, H.H. Meyer,
Cdc48/p97 promotes reformation of the nucleus by extracting the kinase Aurora
B from chromatin, Nature 450 (2007) 1258–1262.
[23] Y. Ye, H.H. Meyer, T.A. Rapoport, The AAA ATPase Cdc48/p97 and its partners
transport proteins from the ER into the cytosol, Nature 414 (2001) 652–656.
[24] E. Jarosch, C. Taxis, C. Volkwein, J. Bordallo, D. Finley, D.H. Wolf, T. Sommer,
Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase
Cdc48, Nat. Cell Biol. 4 (2002) 134–139.
[25] E. Rabinovich, A. Keren, K.U. Frohlich, N. Diamant, S. Bar Nun, AAA-ATPase
p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-
associated protein degradation, Mol. Cell. Biol. 22 (2002) 626–634.
[26] T. Hoppe, K.Matuschewski, M. Rape, S. Schlenker, H.D. Ulrich, S. Jentsch, Activation
of a membrane-bound transcription factor by regulated ubiquitin/proteasome-
dependent processing, Cell 102 (2000) 577–586.
[27] R.M.Dai, C.C. Li, Valosin-containingprotein isamulti-ubiquitinchain-targeting factor
required in ubiquitin-proteasome degradation, Nat. Cell Biol. 3 (2001) 740–744.
[28] R.C. Janiesch, J. Kim, J. Mouysset, R. Barikbin, H. Lochmuller, G. Cassata, S. Krause,
T. Hoppe, The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly
to human myopathy, Nat. Cell Biol. 9 (2007) 379–390.
[29] Y. Sasagawa,M. Otani, N. Higashitani, A. Higashitani, K. Sato, T. Ogura, K. Yamanaka,
Caenorhabditis elegans p97 controls germline-speciﬁc sex determination by
controlling the TRA-1 level in a CUL-2-dependent manner, J. Cell Sci. 122 (2009)
3663–3672.
[30] D. Moir, S.E. Stewart, B.C. Osmond, D. Botstein, Cold-sensitive cell-division-cycle
mutations of yeast: isolation, properties, and pseudoreversion studies, Genetics
100 (1982) 547–563.
[31] K. Cao, R. Nakajima, H.H. Meyer, Y. Zheng, The AAA-ATPase Cdc48/p97 regulates
spindle disassembly at the end of mitosis, Cell 115 (2003) 355–367.
[32] X. Fu, C.Ng,D. Feng, C. Liang, Cdc48p is required for the cell cycle commitment point
at Start via degradationof theG1-CDK inhibitor Far1p, J. Cell Biol. 163 (2003)21–26.
[33] J. Mouysset, A. Deichsel, S. Moser, C. Hoege, A.A. Hyman, A. Gartner, T. Hoppe,
Cell cycle progression requires the CDC-48UFD-1/NPL-4 complex for efﬁcient
DNA replication, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 12879–12884.
[34] F.E. Indig, J.J. Patridge, C. von Kobbe, M.I. Aladjem, M. Latterich, V.A. Bohr, Werner
syndrome protein directly binds to the AAA ATPase p97/VCP in an ATP-
dependent fashion, J. Struct. Biol. 146 (2004) 251–259.
[35] J.J. Partridge, J.O. Lopreiato Jr., M. Latterich, F.E. Indig, DNA damage modulates
nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP, Mol.
Biol. Cell 14 (2003) 4221–4229.
[36] H. Higashiyama, F. Hirose, M. Yamaguchi, Y.H. Inoue, N. Fujikake, A. Matsukage,
A. Kakizuka, Identiﬁcation of ter94, Drosophila VCP, as a modulator of
polyglutamine-induced neurodegeneration, Cell Death Differ. 9 (2002) 264–273.
[37] T. Kobayashi, A. Manno, A. Kakizuka, Involvement of valosin-containing protein
(VCP)/p97 in the formation and clearance of abnormal protein aggregates, Genes
Cells 12 (2007) 889–901.
[38] C. Song, Q. Wang, C.C.H. Li, Characterization of the aggregation-prevention
activity of p97/VCP-containing protein, Biochemistry 46 (2007) 14889–14898.
[39] S. Nishikori, K. Yamanaka, T. Sakurai, M. Esaki, T. Ogura, p97 homologs from
Caenorhabditis elegans, CDC-48.1 and CDC-48.2, suppress the aggregate
formation of huntingtin exon1 containing expanded polyQ repeat, Genes Cells
13 (2008) 827–838.
[40] J.S. Ju, R.A. Fuentealba, S.E. Miller, E. Jackson, D. Piwnica-Worms, R.H. Baloh,
C.C. Weihl, Valosin-containing protein (VCP) is required for autophagy and is
disrupted in VCP disease, J. Cell Biol. 187 (2009) 875–888.[41] J. Vesa, H. Su, G.D. Watts, S. Krause, M.C. Walter, B. Martin, C. Smith, D.C. Wallace,
V.E. Kimonis, Valosin containing protein associated inclusion body myopathy:
abnormal vacuolization, autophagy and cell fusion in myoblasts, Neuromuscul.
Disord. 19 (2009) 766–772.
[42] E. Tresse, F.A. Salomons, J. Vesa, L.C. Bott, V. Kimonis, T.P. Yao, N.P. Dantuma,
J.P. Taylor, VCP/p97 is essential for maturation of ubiquitin-containing
autophagosomes and this function is impaired by mutations that cause
IBMPFD, Autophagy 6 (2010) 217–227.
[43] R. Krick, S. Bremer, E.Welter, P. Schlotterhose, Y.Muehe, E.-L. Eskelinen,M. Thumm,
Cdc48/p97 and Shp1/p47 regulate autophagosome biogenesis in concert with
ubiquitin-like Atg8, J. Cell Biol. 190 (2010) 965–973.
[44] A. Tanaka, M.M. Cleland, S. Xu, D.P. Narendra, D.F. Suen, M. Karbowski, R.J. Youle,
Proteasome and p97 mediate mitophagy and degradation of mitofusins induced
by Parkin, J. Cell Biol. 191 (2010) 1367–1380.
[45] Y. Ye, Diverse functions with a common regulator: ubiquitin takes command of
an AAA ATPase, J. Struct. Biol. 156 (2006) 29–40.
[46] C. Schuberth, A. Buchberger, UBX domain proteins: major regulators of the AAA
ATPase Cdc48/p97, Cell. Mol. Life Sci. 65 (2008) 2360–2371.
[47] L. Madsen, M. Seeger, C.A. Semple, R. Hartmann-Petersen, New ATPase
regulators—p97 goes to the PUB, Int. J. Biochem. Cell Biol. 41 (2009) 2380–2388.
[48] G.D. Watts, J. Wymer, M.J. Kovach, S.G. Mehta, S. Mumm, D. Darvish, A. Pestronk,
M.P. Whyte, V.E. Kimonis, Inclusion body myopathy associated with Paget
disease of bone and frontotemporal dementia is caused by mutant valosin-
containing protein, Nat. Genet. 36 (2004) 377–381.
[49] C.C. Weihl, A. Pestronk, V.E. Kimonis, Valosin-containing protein disease:
Inclusion body myopathy with Paget's disease of the bone and fronto-temporal
dementia, Neuromuscul. Disord. 19 (2009) 308–315.
[50] J.O. Johnson, J. Mandrioli, M. Benatar, Y. Abramzon, V.M. Van Deerlin, J.Q.
Trojanowski, J.R. Gibbs, M. Brunetti, S. Gronka, J. Wuu, J. Ding, L. McCluskey,
M. Martinez-Lage, D. Falcone, D.G. Hernandez, S. Arepalli, S. Chong, J.C.
Schymick, J. Rothstein, F. Landi, Y.D. Wang, A. Calvo, G. Mora, M. Sabatelli, M.
R. Monsurrò, S. Battistini, F. Salvi, R. Spataro, P. Sola, G. Borghero, ITALSGEN
Consortium, G. Galassi, S.W. Scholz, J.P. Taylor, G. Restagno, A. Chiò, B.J.
Traynor, Exome sequencing reveals VCP mutations as a cause of familial ALS,
Neuron 68 (2010) 857–864.
[51] Q. Wang, C. Song, C.C.H. Li, Molecular perspectives on p97-VCP: progress in
understanding its structure and diverse biological functions, J. Struct. Biol. 146
(2004) 44–57.
[52] K. Uchiyama, H. Kondo, p97/p47-mediated biogenesis of Golgi and ER, J. Biochem.
137 (2005) 115–119.
[53] R.J. Braun, H. Zischka, Mechanisms of Cdc48/VCP-mediated cell death—from yeast
apoptosis to human disease, Biochim. Biophys. Acta 1783 (2008) 1418–1435.
[54] D.S. Haines, p97-containing complexes in proliferation control and cancer:
emerging culprits or guilt by association? Genes Cancer 1 (2010) 753–763.
[55] E. Chapman, A.N. Fry, M.J. Kang, The complexities of p97 function in health and
disease, Mol. Biosyst. 7 (2011) 700–710.
[56] M.H. Glickman, A. Ciechanover, The ubiquitin-proteasome proteolytic
pathway: destruction for the sake of construction, Physiol. Rev. 82 (2002)
373–428.
[57] X. Zhong, Y. Shen, P. Ballar, A. Apostolou, R. Agami, S. Fang, AAA ATPase
p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for
endoplasmic reticulum-associated degradation, J. Biol. Chem. 279 (2004)
45676–45684.
[58] B.N. Lilley, H.L. Ploegh, Multiprotein complexes that link dislocation, ubiquitina-
tion, and extraction of misfolded proteins from the endoplasmic reticulum
membrane, Proc. Natl. Acad. Sci. U. S. A 102 (2005) 14296–14301.
[59] Y. Ye, Y. Shibata, M. Kikkert, S. van Voorden, E.Wiertz, T.A. Rapoport, Recruitment
of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the
endoplasmic reticulum membrane, Proc. Natl. Acad. Sci. U. S. A. 102 (2005)
14132–14138.
[60] G. Alexandru, J. Graumann, G.T. Smith, N.J. Kolawa, R. Fang, R.J. Deshaies, UBXD7
binds multiple ubiquitin ligases and implicates p97 in HIF1α turnover, Cell 134
(2008) 804–816.
[61] R. Ellis, T. Schedl, Sex determination in the germ line, in: Wormbook (Ed.), The C.
elegans Research Community, WormBook,(April), http://www.wormbook.org,
doi:10.1895/wormbook.1.82.1.
[62] J. Kimble, S.L. Crittenden, Controls of germline stem cells, entry into meiosis, and
the sperm/oocytes decision in C. elegans, Annu. Rev. Cell Dev. Biol. 23 (2007)
405–433.
[63] A. Mehra, J. Gaudet, L. Heck, P.E. Kuwabara, A.M. Spence, Negative regulation of
male development in Caenorhabditis elegans by a protein-protein interaction
between TRA-2A and FEM-3, Genes Dev. 13 (1999) 1453–1463.
[64] N.G. Starostina, J.M. Lim, M. Schvarzstein, L. Wells, A.M. Spence, E.T. Kipreos, A
CUL-2 ubiquitin ligase containing three FEM proteins degrades TRA-1 to regulate
C. elegans sex determination, Mol. Cell 13 (2007) 127–139.
[65] M. Schvarzstein, A.M. Spence, The C. elegans sex-determining GLI protein TRA-1A
is regulated by sex-speciﬁc proteolysis, Dev. Cell 11 (2006) 733–740.
[66] S. Yamauchi, K. Yamanaka, T. Ogura, Comparative analysis of expression of two
p97 homologues in Caenorhabditis elegans, Biochem. Biophys. Res. Commun. 345
(2006) 746–753.
[67] S. Yamauchi, N. Higashitani, M. Otani, A. Higashitani, T. Ogura, K. Yamanaka,
Involvement of HMG-12 and CAR-1 in the cdc-48.1 expression of Caenorhabditis
elegans, Dev. Biol. 318 (2008) 348–359.
[68] Y. Sasagawa, K. Yamanaka, Y. Saito-Sasagawa, T. Ogura, Caenorhabditis elegans
UBX cofactors for CDC-48/p97 control spermatogenesis, Genes Cells 15 (2010)
1201–1215.
136 K. Yamanaka et al. / Biochimica et Biophysica Acta 1823 (2012) 130–137[69] N. Shcherbik, T. Zoladek, J.T. Nickels, D.S. Haines, Rsp5p is required for ER bound
Mga2p120 polyubiquitination and release of the processed/tethered transacti-
vator Mga2p90, Curr. Biol. 13 (2003) 1227–1233.
[70] N. Shcherbik, D.S. Haines, Cdc48pNpl4p/Ufd1p binds and segregates membrane-
anchored/tethered complexes via a polyubiquitin signal present on the anchors,
Mol. Cell 25 (2007) 385–397.
[71] M.E. Sowa, E.J. Bennett, S.P. Gygi, J.W. Harper, Deﬁning the human deubiquiti-
nating enzymes interaction land scape, Cell 138 (2009) 389–403.
[72] Y. Kawaguchi, T. Okamoto, M. Taniwaki, M. Aizawa, M. Inoue, S. Katayama, H.
Kawakami, S. Nakamura, M. Nishimura, I. Akiguchi, CAG expansions in a novel
gene for Machado–Joseph disease at chromosome 14q32.1, Nat. Genet. 8 (1994)
221–228.
[73] B. Burnett, F. Li, R.N. Pittman, The polyglutamine neurodegenerative protein
ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity,
Hum. Mol. Genet. 12 (2003) 3195–3205.
[74] E.W. Doss-Pepe, E.S. Stenroos, W.G. Johnson, K. Madura, Ataxin-3 interactions
with Rad23 and valosin-containing protein and its associations with ubiquitin
chains and the proteasome are consistent with a role in ubiquitin-mediated
proteolysis, Mol. Cell. Biol. 23 (2003) 6469–6483.
[75] X. Zhong, R.N. Pittman, Ataxin-3 binds VCP/p97 and regulates retrotranslocation
of ERAD substrates, Hum. Mol. Genet. 15 (2006) 2409–2420.
[76] Q. Wang, L. Li, Y. Ye, Regulation of retrotranslocation by p97-associated
deubiquitinating enzyme ataxin-3, J. Cell Biol. 174 (2006) 963–971.
[77] V. Fernandez-Saiz, A. Buchberger, Imbalances in p97 co-factor interactions in
human proteinopathy, EMBO Rep. 11 (2010) 479–485.
[78] K. Kuhlbrodt, P.C. Janiesch, E. Kevei, A. Segref, R. Barikbin, T. Hoppe, The
Machado–Joseph disease deubiquitylase ATX-3 couples longevity and proteos-
tasis, Nat. Cell Biol. 13 (2011) 272–281.
[79] C. Leidhold, W. Voos, Chaperones and proteases—guardians of protein integrity
in eukaryotic organelles, Ann. N. Y. Acad. Sci. 1113 (2007) 72–86.
[80] Q. Zhong, W. Gao, F. Du, X. Wang, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase,
catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis, Cell 121
(2005) 108501095.
[81] A. Neutzner, R.J. Youle, M. Karbowski, Outer mitochondrial membrane
protein degradation by the proteasome, Novartis Found Symp. 287 (2007)
4–14.
[82] E. Ziviani, R.N. Tao, A.J. Whitworth, Drosophila parkin requires PINK1 for
mitochondrial translocation and ubiquitinates mitofusin, Proc. Natl. Acad. Sci.
U. S. A. 107 (2010) 5018–5023.
[83] T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M.
Yokochi, Y. Mizuno, N. Shimizu, Mutations in the parkin gene cause autosomal
recessive juvenile parkinsonism, Nature 392 (1998) 605–608.
[84] D. Narendra, A. Tanaka, D.F. Suen, R.J. Youle, Parkin is recruited selectively to
impaired mitochondria and promotes their autophagy, J. Cell Biol. 183 (2008)
795–803.
[85] H. Shimura, N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa, S. Minoshima, N. Shimizu,
N. Iwai, T. Chiba, K. Tanaka, T. Suzuki, Familial Parkinson disease gene product,
parkin, is a ubiquitin-protein ligase, Nat. Genet. 25 (2000) 302–305.
[86] N. Nakamura, S. Hirose, Regulation of mitochondrial morphology by USP30, a
deubiquitinating enzyme present in the mitochondrial outer membrane, Mol.
Biol. Cell 19 (2008) 1903–1911.
[87] N.J. Krogan, G. Cagney, H. Yu, G. Zhong, X. Guo, A. Ignatchenko, J. Li, S. Pu, N.
Datta, A.P. Tikuisis, T. Punna, J.M. Peregrín-Alvarez, M. Shales, X. Zhang, M.
Davey, M.D. Robinson, A. Paccanaro, J.E. Bray, A. Sheung, B. Beattie, D.P. Richards,
V. Canadien, A. Lalev, F. Mena, P. Wong, A. Starostine, M.M. Canete, J. Vlasblom, S.
Wu, C. Orsi, S.R. Collins, S. Chandran, R. Haw, J.J. Rilstone, K. Gandi, N.J.
Thompson, G. Musso, P. St Onge, S. Ghanny, M.H. Lam, G. Butland, A.M. Altaf-Ul,
S. Kanaya, A. Shilatifard, E. O'Shea, J.S. Weissman, C.J. Ingles, T.R. Hughes, J.
Parkinson, M. Gerstein, S.J. Wodak, A. Emili, J.F. Greenblatt, Global landscape of
protein complexes in the yeast Saccharomyces cerevisiae, Nature 440 (2006)
637–643.
[88] H.X. Hao, J. Rutter, Revealing human disease genes through analysis of the yeast
mitochondrial proteome, Cell Cycle 8 (2009) 4007–4008.
[89] J.M. Heo, N. Livnat-Levanon, E.B. Taylor, K.T. Jones, N. Dephoure, J. Ring, J. Xie, J.L.
Brodsky, F. Madeo, S.P. Gygi, K. Ashraﬁ, M.H. Glickman, J. Rutter, A stress-
responsive system for mitochondrial protein degradation, Mol. Cell 40 (2010)
465–480.
[90] J.R. Tran, L.R. Tomsic, J.L. Brodsky, A Cdc48p-associated factor modulates
endoplasmic reticulum-associated degradation, cell stress, and ubiquitinated
protein homeostasis, J. Biol. Chem. 286 (2011) 5744–5755.
[91] S. Xu, G. Peng, Y. Wang, S. Fang, M. Karbowski, The AAA-ATPase p97 is essential
for outer mitochondrial membrane protein turnover, Mol. Biol. Cell 22 (2011)
291–300.
[92] L.J. Pallanck, Culling sick mitochondria from the herd, J. Cell. Biol. 191 (2010)
1225–1227.
[93] J.B. Guinto, G.P. Ritson, J.P. Taylor, M.S. Forman, Valosin-containing protein and
the pathogenesis of frontotemporal dementia associated with inclusion body
myopathy, Acta Neuropathol. 114 (2007) 55–61.
[94] V.E. Kimonis, E. Fulchiero, J. Vesa, G. Watts, VCP disease associated with
myopathy, Paget disease of bone and frontotemporal dementia: review of a
unique disorder, Biochim. Biophys. Acta 1782 (2008) 744–748.
[95] J.S. Ju, C.C. Weihl, Inclusion body myopathy, Paget's disease of the bone and
fronto-temporal dementia: a disorder of autophagy, Hum. Mol. Genet. 19 (2010)
R38–R45.
[96] B. DeLaBarre, A.T. Brunger, Nucleotide dependent motion and mechanism of
action of p97/VCP, J. Mol. Biol. 347 (2005) 437–452.[97] C.U. Hubbers, C.S. Clemen, K. Kesper, A. Boddrich, A. Hoffmann, O. Kamarainen, K.
Tolksdorf, M. Stumpf, J. Reichelt, U. Roth, S. Krause, G. Watts, V. Kimonis, M.P.
Wattjes, J. Reimann, D.R. Thal, K. Biermann, B.O. Evert, H. Lochmuller, E.E.
Wanker, B.G. Schoser, A.A. Noegel, R. Schroder, Pathological consequences of VCP
mutations on human striated muscle, Brain 130 (2007) 381–393.
[98] W.K. Tang, D. Li, C.C. Li, L. Esser, R. Dai, L. Guo, D. Xia, A novel ATP-dependent
conformation in p97 N-D1 fragment revealed by crystal structures of disease-
related mutants, EMBO J. 29 (2010) 2217–2229.
[99] A. Manno, M. Noguchi, J. Fukushi, Y. Motohashi, A. Kakizuka, Enhanced ATPase
activities as a primary defect of mutant valosin-containing proteins that cause
inclusion body myopathy associated with Paget disease of bone and fronto-
temporal dementia, Genes Cells 15 (2010) 911–922.
[100] D. Halawani, A.C. LeBlanc, I. Rouiller, S.W. Michnick, M.J. Servant, M. Latterich,
Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2
domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring
conformation, Mol. Cell. Biol. 29 (2009) 4484–4494.
[101] C.C. Weihl, S. Dalal, A. Pestronk, P.I. Hanson, Inclusion bodymyopathy-associated
mutations in p97/VCP impair endoplasmic reticulum-associated degradation,
Hum. Mol. Genet. 15 (2006) 189–199.
[102] J.S. Ju, S.E. Miller, P.I. Hanson, C.C. Weihl, Impaired protein aggregate handling
and clearance underlie the pathogenesis of p97/VCP-associated disease, J. Biol.
Chem. 283 (2008) 30289–30299.
[103] S. Dalal, M.F. Rosser, D.M. Cyr, P.I. Hanson, Distinct roles for the AAA ATPases NSF
and p97 in the secretory pathway, Mol. Biol. Cell 15 (2004) 637–648.
[104] C. Wojcik, M. Yano, G.N. DeMartino, RNA interference of valosin-containing
protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/protea-
some-dependent proteolysis, J. Cell Sci. 117 (2004) 281–292.
[105] D. Glick, S. Barth, K.F. Macleod, Autophagy: cellular and molecular mechanisms,
J. Pathol. 221 (2010) 3–12.
[106] C.C. Weihl, S.E. Miller, P.I. Hanson, A. Pestronk, Transgenic expression of
inclusion body myopathy associated mutant p97/VCP causes weakness and
ubiquitinated protein inclusions in mice, Hum. Mol. Genet. 16 (2007) 919–928.
[107] M. Badadani, A. Nalbandian, G.D.Watts, J. Vesa, M. Kitazawa, H. Su, J. Tanaja, E. Dec,
D.C. Wallace, J. Mukherjee, V. Caiozzo, M. Warman, V.E. Kimonis, VCP associated
inclusionbodymyopathyandPaget diseaseof boneknock-inmousemodel exhibits
tissue pathology typical of human disease, PLoS ONE 5 (2010) e13183.
[108] M. Neumann, I.R. Mackenzie, N.J. Cairns, P.L. Boyer, W.R. Markesbery, C.D. Smith,
J.P. Taylor, H.A. Kretzschmar, V.E. Kimonis, M.S. Forman, TDP-43 in the ubiquitin
pathology of frontotemporal dementia with VCP gene mutations, J. Neuropathol.
Exp. Neurol. 66 (2007) 152–157.
[109] C.C. Weihl, P. Temiz, S.E. Miller, G. Watts, C. Smith, M. Forman, P.I. Hanson, V.
Kimonis, A. Pestronk, TDP-43 accumulation in inclusion body myopathy muscle
suggests a common pathogenic mechanism with frontotemporal dementia,
J. Neurol. Neurosurg. Psychiatry 79 (2008) 1186–1189.
[110] M.S. Forman, I.R. Mackenzie, N.J. Cairns, E. Swanson, P.J. Boyer, D.A. Drachman,
B.S. Jhaveri, J.H. Karlawish, A. Pestronk, T.W. Smith, P.H. Tu, G.D. Watts, W.R.
Markesbery, C.D. Smith, V.E. Kimonis, Novel ubiquitin neuropathology in
frontotemporal dementia with valosin-containing protein gene mutations,
J. Neuropathol. Exp. Neurol. 65 (2006) 571–581.
[111] Y.M. Ayala, S. Pantano, A. D'Ambrogio, E. Buratti, A. Brindisi, C. Marchetti, M.
Romano, F.E. Baralle, Human, Drosophila, and C. elegans TDP43: nucleic acid
binding properties and splicing regulatory function, J. Mol. Biol. 348 (2005)
575–588.
[112] S.T. Warraich, S. Yang, G.A. Nicholson, I.P. Blair, TDP-43: A DNA and RNA binding
protein with roles in neurodegenerative diseases, Int. J. Biochem. Cell Biol. 42
(2010) 1606–1609.
[113] C. Lagier-Tourenne, M. Polymenidou, D.W. Cleveland, TDP-43 and FUS/TLS:
emerging roles in RNA processing and neurodegeneration, Hum. Mol. Genet. 19
(2010) R46–R64.
[114] M. Neumann, D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, T.T. Chou, J.
Bruce, T. Schuck, M. Grossman, C.M. Clark, L.F. McCluskey, B.L. Miller, E. Masliah,
I.R. Mackenzie, H. Feldman, W. Feiden, H.A. Kretzschmar, J.Q. Trojanowski, V.M.
Lee, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyo-
trophic lateral sclerosis, Science 314 (2006) 130–133.
[115] Y.M. Ayala, P. Zago, A. D'Ambrogio, Y.F. Xu, L. Petrucelli, E. Buratti, F.E. Baralle,
Structural determinants of the cellular localization and shuttling of TDP-43,
J. Cell Sci. 121 (2008) 3778–3785.
[116] M.J. Winton, L.M. Igaz, M.M. Wong, L.K. Kwong, J.Q. Trojanowski, V.M. Lee,
Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43)
induces disease-like redistribution, sequestration, and aggregate formation,
J. Biol. Chem. 283 (2008) 13302–13309.
[117] X. Wang, H. Fan, Z. Ying, B. Li, H. Wang, G. Wang, Degradation of TDP-43 and its
pathogenic form by autophagy and the ubiquitin-proteasome system, Neurosci.
Lett. 469 (2010) 112–116.
[118] G.P. Ritson, S.K. Custer, B.D. Freibaum, J.B. Guinto, D. Geffel, J. Moore, W. Tang, M.
J. Winton, M. Neumann, J.Q. Trojanowski, V.M.-Y. Lee, M.S. Forman, J.P. Taylor,
TDP-43 mediates degeneration in a novel Drosophilamodel of disease caused by
mutations in VCP/p97, J. Neurosci. 30 (2010) 7729–7739.
[119] F. Geser, M. Martinez-Lage, L.K. Kwong, V.M. Lee, J.Q. Trojanowski, Amyotrophic
lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 disease,
J. Neurol. 256 (2009) 1205–1214.
[120] L. Miguel, T. Frebourg, D. Campion, M. Lecourtois, Both cytoplasmic and nuclear
accumulations of the protein are neurotoxic in Drosophila models of TDP-43
proteinopathies, Neurobiol. Dis. 41 (2011) 398–406.
[121] Y.C. Chang,W.T. Hung, Y.C. Chang, H.C. Chang, A.S. Chiang, G.R. Jackson, T.K. Sang,
Pathogenic VCP/TER94 alleles are dominant actives and contribute to
137K. Yamanaka et al. / Biochimica et Biophysica Acta 1823 (2012) 130–137neurodegeneration by altering cellular ATP level in Drosophila IBMPFD model,
PLoS Genet. 7 (2011) e1001288.
[122] S.A. Greenberg, G.D. Watts, V.E. Kimonis, A.A. Amato, J.L. Pinkus, Nuclear
localization of valosin-containing protein in normal muscle and muscle affected
by inclusion-body myositis, Muscle Nerve 36 (2007) 447–454.
[123] A. Deichsel, J. Mouysset, T. Hoppe, The ubiquitin-selective chaperone CDC-48/p97,
a new player in DNA replication, Cell Cycle 8 (2009) 185–190.
[124] H. Meyer, A. Drozdowska, G. Dobrynin, A role for CDC48/p97 and Aurora B in
controlling chromatin condensation during exit frommitosis, Biochem. Cell Biol.
88 (2010) 23–28.
[125] N. Ikai, M. Yanagida, Cdc48 is required for the stability of Cut1/separase in
mitotic anaphase, J. Struct. Biol. 156 (2006) 50–61.
[126] J.Y. Hsu, Z.W. Sun, X. Li, M. Reuben, K. Tatchell, D.K. Bishop, J.M. Grushcow, C.J.
Brame, J.A. Caldwell, D.F. Hunt, R. Lin, M.M. Smith, C.D. Allis, Mitotic
phosphorylation of histonH3 is governed by Ipl1/aurora kinase and Glc7/PP1
phosphatase in budding yeast and nematodes, Cell 102 (2000) 279–291.
[127] G. Dobrynin, O. Popp, T. Romer, S. Bremer, M.H.A. Schmitz, D.W. Gerlich, H.
Meyer, Cdc48/p97-Ufd1-Npl4 antagonizes Aurora B during chromosome
segregation in HeLa cells, J. Cell Sci. 124 (2011) 1571–1580.
[128] Y.L. Cheng, R.H. Chen, The AAA-ATPase Cdc48 and cofactor Shp1 promote
chromosome bi-orientation by balancing Aurora B activity, J. Cell Sci. 123 (2010)
2025–2034.
[129] P. Pasierbek, M. Jantsch, M. Melcher, A. Schleiffer, D. Schweizer, J. Loidl, A
Caenorhabditis elegans cohesion protein with functions in meiotic chromosome
pairing and disjunction, Genes Dev. 15 (2001) 1349–1360.
[130] E. Rogers, J.D. Bishop, J.A.Waddle, J.M. Schumacher, R. Lin, The aurora kinase AIR-
2 functions in the release of chromosome cohesion in Caenorhabditis elegans
meiosis, J. Cell Biol. 157 (2002) 219–229.
[131] Y. Sasagawa, K. Yamanaka, S. Nishikori, T. Ogura, Caenorhabditis elegans
p97/CDC-48 is critical for progression of meiosis I, Biochem. Biophys. Res.
Commun. 358 (2007) 920–924.
[132] S. Heubes, O. Stemmann, The AAA-ATPase p97-Ufd1-Npl4 is required for ERAD
but not for spindle disassembly in Xenopus egg extracts, J. Cell Sci. 120 (2007)
1325–1329.
[133] T. Yamada, K. Okuhara, A. Iwamatsu, H. Seo, T. Shibata, H. Murofushi, p97
ATPase, an ATPase involved in membrane fusion, interacts with DNA
unwinding factor (DUF) that functions in DNA replication, FEBS Lett. 466
(2000) 289–291.[134] M.E. Caruso, S. Jenna, M. Bouchecareilh, D.L. Baillie, D. Boismenu, D. Halawani, M.
Latterich, E. Chevet, GTPase-mediated regulation of the unfolded protein
response in Caenorhabditis elegans is dependent on the AAA+ ATPase CDC-48,
Mol. Cell. Biol. 28 (2008) 4261–4274.
[135] R. Verma, R. Oania, R. Fang, G.T. Smith, R.J. Deshaies, Cdc48/p97 mediates UV-
dependent turnover of RNA Pol II, Mol. Cell 41 (2011) 82–92.
[136] Q. Wang, L. Li, Y. Ye, Inhibition of p97-dependent protein degradation by
eeyarestatin I, J. Biol. Chem. 283 (2008) 7445–7454.
[137] Q. Wang, B.A. Shinkre, J. Lee, M.A. Weniger, Y. Liu, W. Chen, A. Wiestner, W.C.
Trenkle, Y. Ye, The ERAD inhibitor eeyarestatin I is a bifunctional compound with
a membrane-binding domain and a p97/VCP inhibitory group, PLoS ONE 5
(2010) e15479.
[138] M.G. Bursavich, D.P. Parker, J.A. Willardsen, Z.H. Gao, T. Davis, K. Ostanin, R.
Robinson, A. Peterson, D.M. Cimbora, J.F. Zhu, B. Richards, 2-Anilino-4-aryl-1,3-
thiazole inhibitors of valosin-containing protein (VCP or p97), Bioorg. Med.
Chem. Lett. 20 (2010) 1677–1679.
[139] T.F. Chou, R.J. Dashaies, Quantitative cell-based protein degradation assays to
identify and classify drugs that target the ubiquitin-proteasome system, J. Biol.
Chem. 286 (2011) 16546–16554.
[140] T.F. Chou, S.J. Brown, D. Minond, B.E. Nordin, K. Li, A.C. Jones, P. Chase, P.R.
Porubsky, B.M. Stoltz, F.J. Schoenen, M.P. Patricelli, P. Hodder, H. Rosen, R.J.
Deshaies, Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent
and autophagic protein clearance pathways, Proc. Natl. Sci. Acad. U. S. A. 108
(2011) 4834–4839.
[141] E. Cubedo, L. Cordeu, E. Bandres, A. Rebollo, R. Malumbres, C. Sanmartin, M. Font,
J.A. Palop, J. Garcia-Foncillas, New symmetrical quinazoline derivatives selec-
tively induce apoptosis in human cancer cells, Cancer Biol. Ther. 5 (2006)
850–859.
[142] J. Adams, The development of proteasome inhibitors as anticancer drugs, Cancer
Cell 5 (2004) 417–421.
[143] S. Yamamoto, Y. Tomita, Y. Hoshida, S. Takiguchi, Y. Fujiwara, T. Yasuda, M. Yano,
S. Nakamori, M. Sakon, M. Monden, K. Aozasa, Expression level of valosin-
containing protein is strongly associated with progression and prognosis of
gastric carcinoma, J. Clin. Oncol. 21 (2003) 2537–2544.
[144] S. Yamamoto, Y. Tomita, T. Uruno, Y. Hoshida, Y. Qiu, N. Iizuka, I. Nakamichi, A.
Miyauchi, K. Aozasa, Increased expression of valosin-containing protein (p97) is
correlated with disease recurrence in follicular thyroid cancer, Ann. Surg. Oncol.
12 (2005) 925–934.
